Biocryst Pharmaceuticals (BCRX) Share-based Compensation: 2009-2024
Historic Share-based Compensation for Biocryst Pharmaceuticals (BCRX) over the last 16 years, with Dec 2024 value amounting to $65.4 million.
- Biocryst Pharmaceuticals' Share-based Compensation fell 46.73% to $1.9 million in Q4 2015 from the same period last year, while for Dec 2015 it was $9.7 million, marking a year-over-year decrease of 4.64%. This contributed to the annual value of $65.4 million for FY2024, which is 17.62% up from last year.
- Latest data reveals that Biocryst Pharmaceuticals reported Share-based Compensation of $65.4 million as of FY2024, which was up 17.62% from $55.6 million recorded in FY2023.
- In the past 5 years, Biocryst Pharmaceuticals' Share-based Compensation registered a high of $65.4 million during FY2024, and its lowest value of $14.8 million during FY2020.
- Its 3-year average for Share-based Compensation is $55.2 million, with a median of $55.6 million in 2023.
- Its Share-based Compensation has fluctuated over the past 5 years, first decreased by 16.51% in 2020, then spiked by 134.15% in 2021.
- Over the past 5 years, Biocryst Pharmaceuticals' Share-based Compensation (Yearly) stood at $14.8 million in 2020, then spiked by 134.15% to $34.6 million in 2021, then increased by 29.04% to $44.7 million in 2022, then rose by 24.42% to $55.6 million in 2023, then climbed by 17.62% to $65.4 million in 2024.